Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 22,344 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ACTIVE Clear all
Completed Phase 3 Interventional

Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects.

NCT05695781
View directory record Official record
Conditions
Dry Eye Disease
Interventions
BRM421 Ophthalmic Solution, Vehicle
Drug
Lead sponsor
BRIM Biotechnology Inc.
Industry
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Warwick, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes

NCT02296242
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
BVD-523
Drug
Lead sponsor
BioMed Valley Discoveries, Inc
Industry
Eligibility
18 Years to 100 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Los Angeles, California • Atlanta, Georgia • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Not applicable Interventional

Correlation of Laparoscopic Experience and Functional Brain Activation: A PET Scan Study

NCT00860483
View directory record Official record
Conditions
Brain Function
Interventions
observational
Other
Lead sponsor
Northwell Health
Other
Eligibility
25 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected Patients

NCT00089466
View directory record Official record
Conditions
HIV Infections
Interventions
AMD11070
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
3
States / cities
Birmingham, Alabama • Atlanta, Georgia • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Phase 3 Interventional Results available

Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies

NCT05142722
View directory record Official record
Conditions
Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Interventions
Placebo, Obicetrapib
Drug
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years and older
Enrollment
2,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
69
States / cities
Anniston, Alabama • Birmingham, Alabama • Saraland, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics

NCT04226131
View directory record Official record
Conditions
Rheumatoid Arthritis, Healthy Controls
Interventions
Blood Draw, Disease Activity (DAS-28) Assessment, Skeletal Muscle Mitochondrial Respiratory Capacity, Muscle Biopsy, Body Composition, Cardiopulmonary Exercise Test (CPET), Strength Testing, Questionnaires, Skeletal Muscle Biomechanical Property Assessment
Other
Lead sponsor
Duke University
Other
Eligibility
25 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Oct 23, 2026, 5:19 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

NCT06004245
View directory record Official record
Conditions
Advanced Solid Tumors, Colorectal Cancer
Interventions
VVD-133214, Pembrolizumab, Bevacizumab
Drug
Lead sponsor
Vividion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
18
States / cities
Tucson, Arizona • Duarte, California • Irvine, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Not applicable Interventional Results available

Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes

NCT01951339
View directory record Official record
Conditions
Type 2 Diabetes, Cardiovascular Disease
Interventions
Sitagliptin, Glimepiride, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
22 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effects of Gastric Bypass on Blood Levels of Duloxetine

NCT00989157
View directory record Official record
Conditions
Bariatric Surgery
Interventions
Duloxetine
Drug
Lead sponsor
Neuropsychiatric Research Institute, Fargo, North Dakota
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

To Assess the Safety of a Sunscreen Product

NCT02803320
View directory record Official record
Conditions
Sunscreening Agents
Interventions
SPF 50 Y65 110 (BAY 987516)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Building Undergraduate Coping & Knowledge for Stress-Resilience

NCT06885320
View directory record Official record
Conditions
Alcohol Use, College Drinking, Anxiety
Interventions
IMPROVE, HET
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 23, 2026, 5:19 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effects of Graded Protein Intake on Body Composition in Older Adults

NCT04845282
View directory record Official record
Conditions
Sarcopenia
Interventions
Graded Protein plus Resistance Training, RDA Protein plus Resistance Training
Dietary Supplement
Lead sponsor
Wake Forest University
Other
Eligibility
55 Years to 110 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of a Probiotic Strain on Ibuprofen-induced GI Damage

NCT04447924
View directory record Official record
Conditions
Reduction of Small Intestinal Ulceration Risk
Interventions
Bif195, Placebo
Dietary Supplement · Other
Lead sponsor
Chr Hansen
Industry
Eligibility
18 Years to 40 Years
Enrollment
177 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 26, 2021 · Synced Oct 23, 2026, 5:19 PM EDT
Recruiting Not applicable Interventional

Evaluation of Flow Diverter Technology Device for Intracranial Aneurysm (SHIELD)

NCT06793059
View directory record Official record
Conditions
Aneurysm
Interventions
SHIELD
Device
Lead sponsor
Jacobs institute
Other
Eligibility
22 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 23, 2026, 5:19 PM EDT
Recruiting Not applicable Interventional

Impact of a Diabetes Education Mobile Web Application on Patients With Uncontrolled Type 2 Diabetes

NCT05893927
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Education, Lifestyle Modification
Interventions
Diabetes education web site application
Other
Lead sponsor
The Reading Hospital and Medical Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
West Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 23, 2026, 5:19 PM EDT
Completed No phase listed Observational

Active Older Adult Program on Health and Well-being

NCT04897373
View directory record Official record
Conditions
Older Adult
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
55 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 21, 2021 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Not applicable Interventional

Motivational Interviewing Tailored Intervention for Patients With Heart Failure (MITI-HF)

NCT02177656
View directory record Official record
Conditions
Heart Failure
Interventions
Motivational Interviewing tailored intervention
Behavioral
Lead sponsor
Ruth Masterson-Creber
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Phase 2 Interventional Results available

An Open-label Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)

NCT05037851
View directory record Official record
Conditions
Pulmonary Aspergillosis
Interventions
Opelconazole, Standard of Care
Drug
Lead sponsor
Pulmocide Ltd
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
17
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Phase 3 Interventional Results available

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

NCT00464269
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, Brivaracetam 2.5 mg, Brivaracetam 10 mg, Brivaracetam 25 mg
Other · Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 23, 2026, 5:19 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

iPACES v3 MCI NIA Protocol Copied for iPACES v4 PD NINDS

NCT05810454
View directory record Official record
Conditions
Parkinson's Disease, PD, Mild Cognitive Impairment, MCI
Interventions
iPACES (interactive Physical and Cognitive Exercise System), PACE (Physical and Cognitive Exercise)
Device
Lead sponsor
iPACES LLC
Industry
Eligibility
50 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Clifton Park, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 23, 2026, 5:19 PM EDT
Terminated No phase listed Observational

Prospective Tumor Response Evaluation

NCT02787954
View directory record Official record
Conditions
Hepatocellular Cancer, Metastatic Liver Cancer
Interventions
TACE, Y-90, MWA, IRE
Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Oct 23, 2026, 5:19 PM EDT
Suspended Phase 1Phase 2 Interventional

Elimination of Prostate Cancer Treatment Side Effects Using a Nutraceutical

NCT06643494
View directory record Official record
Conditions
Prostate Cancer
Interventions
N-111, Placebo
Dietary Supplement · Other
Lead sponsor
Optimal Health Research
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Stannsoporfin in Neonates

NCT02685137
View directory record Official record
Conditions
Nutritional and Metabolic Diseases
Interventions
stannsoporfin, Sham Injection
Drug · Other
Lead sponsor
InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Industry
Eligibility
12 Hours to 36 Hours
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 23, 2026, 5:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Exercise Study of Function and Pathology for Women With X-linked Adrenoleukodystrophy

NCT01594853
View directory record Official record
Conditions
X-linked Adrenoleukodystrophy
Interventions
exercise training
Behavioral
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
21 Years to 70 Years · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 23, 2026, 5:19 PM EDT